Redeye provides a research update following Smart Eye’s Q1 2024 report. Sales fell short of its expectations, but this was offset by substantially lower costs. As a result, EBITDA came in ahead of our estimates. Further, the pipeline of potential near-term design wins appears promising. Redeye raises its EBITDA estimates for 2024e-2025e and increase its valuation range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases